
Imprimis Recall Unapproved Ophthalmic Injections for Glass Particulates in US
Imprimis NJOF recalled three intraocular ophthalmic injection drug products in December 2025 (as per USFDA Enforcement Reports) in the United
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Please subscribe for latest posts and news with your email address.
Popular: Warning Letters, Recalls
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated (OAI) following an inspection in September 2025. The inspection, conducted by investigators Eileen A. Liu and Claudia Perez-Kasmarski, resulted in a Form 483 citing significant...
An USFDA 483 to CDMO major Catalent’s Baltimore facility (FEI 3015558590) in US cite poor aseptic practices and inadequate maintenance of the facilities. The site manufactures biological drug products, including Delandistrogene Moxeparvovec (Elevidys), and was inspected by FDA investigator Lizaida...
The USFDA has escalated the OAI (Official Action Indicated) classification of the Novo Nordisk–owned Catalent Indiana sterile drug products facility (FEI 3005949964) with a Warning letter. Earlier, the USFDA 483 issued after inspection of the Bloomington, Indiana site had cited...

Imprimis NJOF recalled three intraocular ophthalmic injection drug products in December 2025 (as per USFDA Enforcement Reports) in the United

In November 2025, the USFDA issued a Warning Letter to Bangalore-based Cdymax India following an inspection in April 2025 by

Qvents provides useful tools for QMS processes – Risk Assessments, Continuous Process Validations, Supply Chain Traceability Mapping of Drug Products. The Apps

The USFDA inspection of Hetero Labs Ltd, Unit-IX (FEI: 3009093782), Narasapuram, India, conducted in September 2025 by investigators Tamil Arasu,

Zydus is recalling multiple lots of the antipsychotic drug Chlorpromazine in U.S due to the presence of the impurity N-nitroso-desmethyl-chlorpromazine

The USFDA issued a Warning letter to Hikal’s API facility in Jigani, Bangalore, India. The Warning Letter follows an inspection
Please subscribe for latest posts and news with your email address.
Please subscribe for latest posts and news with your email address.
Be informed about current concerns and focus areas of regulators and auditors; Share your views, comments, hear from industry peers….
List your Job Openings with Qvents; Search for profiles matching the jobs requirements; View profiles, Connect with candidates.
Popular: Warning Letters, Recalls
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated (OAI) following an inspection in September 2025. The inspection, conducted by investigators Eileen A. Liu and Claudia Perez-Kasmarski, resulted in a Form 483 citing significant...
An USFDA 483 to CDMO major Catalent’s Baltimore facility (FEI 3015558590) in US cite poor aseptic practices and inadequate maintenance of the facilities. The site manufactures biological drug products, including Delandistrogene Moxeparvovec (Elevidys), and was inspected by FDA investigator Lizaida...
Syngene International Ltd
Syngene International Ltd
Piramal Pharma Solutions
Piramal Pharma Solutions
Be informed about current concerns and focus areas of regulators and auditors; Share your views, comments, hear from industry peers….
List your Job Openings with Qvents; Search for profiles matching the jobs requirements; View profiles, Connect with candidates.
Popular: Warning Letters, Recalls
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated (OAI) following an inspection in September 2025. The inspection, conducted by investigators Eileen A. Liu and Claudia Perez-Kasmarski, resulted in a Form 483 citing significant...
An USFDA 483 to CDMO major Catalent’s Baltimore facility (FEI 3015558590) in US cite poor aseptic practices and inadequate maintenance of the facilities. The site manufactures biological drug products, including Delandistrogene Moxeparvovec (Elevidys), and was inspected by FDA investigator Lizaida...
Syngene International Ltd
Syngene International Ltd
Piramal Pharma Solutions
Piramal Pharma Solutions

Imprimis NJOF recalled three intraocular ophthalmic injection drug products in December 2025 (as per USFDA Enforcement Reports) in the United

In November 2025, the USFDA issued a Warning Letter to Bangalore-based Cdymax India following an inspection in April 2025 by

Qvents provides useful tools for QMS processes – Risk Assessments, Continuous Process Validations, Supply Chain Traceability Mapping of Drug Products. The Apps

The USFDA inspection of Hetero Labs Ltd, Unit-IX (FEI: 3009093782), Narasapuram, India, conducted in September 2025 by investigators Tamil Arasu,

Zydus is recalling multiple lots of the antipsychotic drug Chlorpromazine in U.S due to the presence of the impurity N-nitroso-desmethyl-chlorpromazine

The USFDA issued a Warning letter to Hikal’s API facility in Jigani, Bangalore, India. The Warning Letter follows an inspection
Popular: Warning Letters, Recalls
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated (OAI) following an inspection in September 2025. The inspection, conducted by investigators Eileen A. Liu and Claudia Perez-Kasmarski, resulted in a Form 483 citing significant...
An USFDA 483 to CDMO major Catalent’s Baltimore facility (FEI 3015558590) in US cite poor aseptic practices and inadequate maintenance of the facilities. The site manufactures biological drug products, including Delandistrogene Moxeparvovec (Elevidys), and was inspected by FDA investigator Lizaida...
The USFDA has escalated the OAI (Official Action Indicated) classification of the Novo Nordisk–owned Catalent Indiana sterile drug products facility (FEI 3005949964) with a Warning letter. Earlier, the USFDA 483 issued after inspection of the Bloomington, Indiana site had cited...